Edicotinib (JNJ-527) is a blood-brain-penetrating, orally active, selective CSF-1R inhibitor (IC50 value is 3.2 nM), with less inhibitory effects on KIT (IC50 value is 20 nM) and FLT3 (IC50 value is 190 nM). Edicotinib (JNJ-527) can block microglial proliferation and attenuate neurodegeneration, and can be used to study Alzheimer's disease and rheumatoid arthritis.

c-Kit:20 nM , FLT3:190 nM, CSF1R:3.2 nM

METHODS: N13 mouse microglial cell line was incubated with Edicotinib (JNJ-527) (0.1, 1, 10, 100, 1000 nM) for 30 min. We characterized the effects of the selective CSF1R inhibitor JNJ-527 on CSF1R activation in vitro. RESULTS Edicotinib (JNJ-527) resulted in a dose-dependent decrease in CSF1R activation and a reduction in ERK1 and ERK2 phosphorylation, with an IC50 of 18.6 nM for CSF1R and 22.5 nM for ERK1/2. [1]

METHODS: ME7 mice were treated with JNJ-527 (3, 10, 30, 100 mg/kg, oral) for five consecutive days at 12 weeks post-induction (wpi), followed by a dose-response experiment to evaluate the potential of Edicotinib (JNJ-527) to block microglial proliferation in ME7-prion mice.
RESULTS Edicotinib (JNJ-527) administered at 30 mg/kg significantly blocked microglial proliferation in ME7-prion mice without altering the population dynamics in the healthy brain. [1]